In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...

InflaRx presented data analyses from a terminated Phase 3 study on the potential treatment for rare skin condition.

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...

InflaRx ( ($IFRX) ) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Ulcerative pyoderma gangrenosum is a rare disease with ...

(RTTNews) - InflaRx N.V. (IFRX) today released detailed analyses from its terminated Phase 3 trial of Vilobelimab in pyoderma gangrenosum. The study was stopped in May 2025 after an Independent Data ...

Leg ulcers form when skin on your leg breaks open. These breaks or sores let air and bacteria travel into your skin’s tissue. For most people, leg ulcers will heal on their own and won’t need medical ...

Please provide your email address to receive an email when new articles are posted on . Patients with pyoderma gangrenosum are at greater risk of all-cause and cause-specific mortality compared with ...

Pyoderma gangrenosum (PG) is a rare, ulcerative skin condition of unknown origin, with an annual incidence of 3 to 10 cases per million people. Skin lesions develop as painful, edematous nodules or ...

Pyoderma gangrenosum was first described as an extraintestinal manifestation of inflammatory bowel disease (IBD) by Brunsting and colleagues in 1930. 1 They described painful enlarging necrotic ulcers ...

It is thought to affect around one in 100,000 people in the UK and US. Pyoderma gangrenosum is believed to occur as a result of a pre-existing condition such as ulcerative colitis, Crohn's disease or ...